Exscientia announces ai drug discovery collaboration with merck kgaa, darmstadt, germany

Oxford, u.k.--(business wire)--exscientia plc (nasdaq: exai) today announced a new collaboration with merck kgaa, darmstadt, germany focused on the discovery of novel small molecule drug candidates across oncology, neuroinflammation and immunology. the multi-year collaboration will utilise exscientia's ai-driven precision drug design and discovery capabilities while leveraging merck kgaa, darmstadt, germany's disease expertise in oncology and neuroinflammation, clinical development capabilities.
EXAI Ratings Summary
EXAI Quant Ranking